A Factorial Study of Combination Hypertension Treatment With Metoprolol Succinate Extended Release and Felodipine Extended ReleaseResults of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT)
نویسندگان
چکیده
منابع مشابه
A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
BACKGROUND Many hypertensive patients require combination therapy to achieve target blood pressure (BP). beta-Blockers and dihydropyridine calcium channel blockers are effective as monotherapy in hypertensive patients and have complementary mechanisms for lowering BP. METHODS This multicenter, randomized, placebo-controlled, unbalanced factorial study included a 4- to 5-week single-blind plac...
متن کاملMetoprolol succinate extended release/hydrochlorothiazide combination tablets
Lowering elevated blood pressure (BP) with drug therapy reduces the risk for catastrophic fatal and nonfatal cardiovascular events such as stroke and myocardial infarction. Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient's BP response, and low response rates with monotherapy, expert groups such as the Joint National Committee (JNC) emphasize...
متن کاملCombined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group.
This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension. After a 4-week, single-blind placebo baseline period, 707 patients with sitting ...
متن کاملHealth expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
BACKGROUND Metoprolol, a selective beta-1 blocker, is available in two different salt forms in the market - metoprolol succinate (MS) and metoprolol tartarate (MT). Both the formulations are Food and Drug Administration approved for the treatment of hypertension. Several studies have shown similar efficacies between the two salts; however, they differ in their pharmacokinetic properties and are...
متن کاملThe effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension.
The objective of this study was to determine whether 3 months of treatment with extended-release metoprolol succinate would reduce C-reactive protein (CRP) levels. Seventy-five patients aged 30-65 years with uncontrolled hypertension were treated with extended-release metoprolol at 25-50 mg, titrated up to 100-200 mg daily. CRP was evaluated at baseline and at 1 and 3 months. In the 61 hyperten...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hypertension
سال: 2006
ISSN: 0895-7061
DOI: 10.1016/j.amjhyper.2005.10.007